# Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

> **NCT06780111** · PHASE1,PHASE2 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 298 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** I-DXd
- **DRUG:** Leucovorin
- **DRUG:** Levoleucovorin
- **DRUG:** 5-Fluorouracil (5-FU)
- **DRUG:** Oxaliplatin
- **BIOLOGICAL:** Sacituzumab tirumotecan
- **DRUG:** Rescue Medication

## Key facts

- **NCT ID:** NCT06780111
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-30
- **Primary completion:** 2032-01-04
- **Final completion:** 2032-01-04
- **Target enrollment:** 298 (ESTIMATED)
- **Last updated:** 2026-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06780111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06780111, "Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06780111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*